New treatment options in mantle cell lymphoma
Mantle cell lymphoma has only recently been generally accepted as a distinct lymphoma entity. Hence, available clinical information is hampered by the lack of a uniformly accepted pathologic classification [11.1]. Furthermore, all series published so far are small, and mostly based on retrospective evaluations.
KeywordsFollicular Lymphoma Mantle Cell Lymphoma Alpha Interferon Bone Marrow Involvement Autologous Hematopoietic Stem Cell Transplantation
Unable to display preview. Download preview PDF.
- 2.Fisher RI, Dahlberg S, Nathwani BN, Banks PM, Miller TP, Grogan TM. A clinical analysis of two indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): a Southwest Oncology Group study. Blood 1995; 85:1075–82.PubMedGoogle Scholar
- 3.Wagner R, Press OW. Educational Booklet. Am Soc Hematol 1995:36–44.Google Scholar
- 14.Meusers P, Engelhard M, Bartels H et al. Mantle cell (centrocytic) lymphoma: long-term survival with advanced disease is possible. Blood 1996; 86 (Suppl 1): 53a.Google Scholar
- 15.Teodorovic I, Pittaluga S, Kluin-Nelemans JC et al. Efficacy of four different regimens in 64 mantle-cell lymphoma cases: clinicopathologic comparison with 498 other non Hodgkin’s lymphoma subtypes. European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 1995; 13: 2819–26.PubMedGoogle Scholar